These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Studies on the role of topoisomerases in general, gene- and strand-specific DNA repair. Stevnsner T; Bohr VA Carcinogenesis; 1993 Sep; 14(9):1841-50. PubMed ID: 8403208 [TBL] [Abstract][Full Text] [Related]
5. The function of DNA topoisomerases in UV-induced DNA excision repair: studies with specific inhibitors in permeabilized human fibroblasts. Popanda O; Thielmann HW Carcinogenesis; 1992 Dec; 13(12):2321-8. PubMed ID: 1335377 [TBL] [Abstract][Full Text] [Related]
6. [Therapeutic approach for colorectal cancer with topoisomerase as a molecular target]. Tsunoda T Nihon Rinsho; 2003 Sep; 61 Suppl 7():472-5. PubMed ID: 14574938 [No Abstract] [Full Text] [Related]
7. DNA topoisomerases: essential enzymes and lethal targets. Chen AY; Liu LF Annu Rev Pharmacol Toxicol; 1994; 34():191-218. PubMed ID: 8042851 [No Abstract] [Full Text] [Related]
8. The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase. Musk SR; Steel GG Br J Cancer; 1990 Sep; 62(3):364-7. PubMed ID: 2169851 [TBL] [Abstract][Full Text] [Related]
9. Topoisomerases in human leukemia. Peereboom D; Charron M; Kaufmann SH Adv Pharmacol; 1994; 29B():33-50. PubMed ID: 8996600 [No Abstract] [Full Text] [Related]
10. [Inhibitors of DNA topoisomerases]. Andoh T Gan To Kagaku Ryoho; 1997 Sep; 24(11):1526-35. PubMed ID: 9309151 [TBL] [Abstract][Full Text] [Related]
11. DNA topoisomerases. Osheroff N Biochim Biophys Acta; 1998 Oct; 1400(1-3):1-2. PubMed ID: 9867354 [No Abstract] [Full Text] [Related]
12. Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. Beck WT; Danks MK; Wolverton JS; Chen M; Granzen B; Kim R; Suttle DP Adv Pharmacol; 1994; 29B():145-69. PubMed ID: 8996606 [No Abstract] [Full Text] [Related]
13. Inhibitory activities of (-)-epigallocatechin-3-O-gallate against topoisomerases I and II. Suzuki K; Yahara S; Hashimoto F; Uyeda M Biol Pharm Bull; 2001 Sep; 24(9):1088-90. PubMed ID: 11558576 [TBL] [Abstract][Full Text] [Related]
14. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. Froelich-Ammon SJ; Osheroff N J Biol Chem; 1995 Sep; 270(37):21429-32. PubMed ID: 7665550 [No Abstract] [Full Text] [Related]
15. Inhibitors of topoisomerases do not block the passage of human lymphocyte chromosomes through mitosis. Sumner AT J Cell Sci; 1992 Sep; 103 ( Pt 1)():105-15. PubMed ID: 1331132 [TBL] [Abstract][Full Text] [Related]
16. DNA topoisomerases as targets for cancer therapy. Ross WE Biochem Pharmacol; 1985 Dec; 34(24):4191-5. PubMed ID: 3000380 [No Abstract] [Full Text] [Related]
17. Drugs acting on DNA topoisomerases: recent advances and future perspectives. Gatto B; Capranico G; Palumbo M Curr Pharm Des; 1999 Mar; 5(3):195-215. PubMed ID: 10066890 [TBL] [Abstract][Full Text] [Related]
18. The twisted 'life' of DNA in the cell: bacterial topoisomerases. Luttinger A Mol Microbiol; 1995 Feb; 15(4):601-6. PubMed ID: 7783632 [TBL] [Abstract][Full Text] [Related]
19. Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Beck WT; Danks MK Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118 [TBL] [Abstract][Full Text] [Related]
20. Rapid chromatin reorganization induced by topoisomerase I-mediated DNA damage. Sun M; Duann P; Lin CT; Zhang H; Liu LF Ann N Y Acad Sci; 2000; 922():340-2. PubMed ID: 11193917 [No Abstract] [Full Text] [Related] [Next] [New Search]